JP2022516045A5 - - Google Patents
Info
- Publication number
- JP2022516045A5 JP2022516045A5 JP2021536413A JP2021536413A JP2022516045A5 JP 2022516045 A5 JP2022516045 A5 JP 2022516045A5 JP 2021536413 A JP2021536413 A JP 2021536413A JP 2021536413 A JP2021536413 A JP 2021536413A JP 2022516045 A5 JP2022516045 A5 JP 2022516045A5
- Authority
- JP
- Japan
- Prior art keywords
- molecule
- protein molecule
- epitope
- nucleic acid
- cell surface
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025046058A JP2025094140A (ja) | 2018-12-21 | 2025-03-19 | エピトープ結合タンパク質にコンジュゲート化されたサポニン |
| JP2025046059A JP2025102831A (ja) | 2018-12-21 | 2025-03-19 | エピトープ結合タンパク質にコンジュゲート化されたサポニン |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL2022283 | 2018-12-21 | ||
| NL2022283 | 2018-12-21 | ||
| NL2023468 | 2019-07-10 | ||
| NL2023468 | 2019-07-10 | ||
| NL2023568 | 2019-07-25 | ||
| NL2023568 | 2019-07-25 | ||
| PCT/EP2019/000334 WO2020126064A1 (en) | 2018-12-21 | 2019-12-09 | Saponin conjugated to epitope-binding proteins |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025046058A Division JP2025094140A (ja) | 2018-12-21 | 2025-03-19 | エピトープ結合タンパク質にコンジュゲート化されたサポニン |
| JP2025046059A Division JP2025102831A (ja) | 2018-12-21 | 2025-03-19 | エピトープ結合タンパク質にコンジュゲート化されたサポニン |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022516045A JP2022516045A (ja) | 2022-02-24 |
| JP2022516045A5 true JP2022516045A5 (cg-RX-API-DMAC7.html) | 2023-01-11 |
| JP7654546B2 JP7654546B2 (ja) | 2025-04-01 |
Family
ID=71101079
Family Applications (11)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021536414A Active JP7593925B2 (ja) | 2018-12-21 | 2019-12-09 | 改善された抗体－オリゴヌクレオチドコンジュゲート |
| JP2021536407A Active JP7652695B2 (ja) | 2018-12-21 | 2019-12-09 | 生物活性な分子のクラスター |
| JP2021536410A Active JP7502301B2 (ja) | 2018-12-21 | 2019-12-09 | 改善された細胞標的化結合分子 |
| JP2021536413A Active JP7654546B2 (ja) | 2018-12-21 | 2019-12-09 | エピトープ結合タンパク質にコンジュゲート化されたサポニン |
| JP2021536411A Active JP7541008B2 (ja) | 2018-12-21 | 2019-12-09 | サポニンコンジュゲート |
| JP2021536412A Active JP7614094B2 (ja) | 2018-12-21 | 2019-12-09 | 薬物コンジュゲート |
| JP2024199932A Pending JP2025015702A (ja) | 2018-12-21 | 2024-11-15 | 改善された抗体－オリゴヌクレオチドコンジュゲート |
| JP2024230339A Pending JP2025041928A (ja) | 2018-12-21 | 2024-12-26 | 薬物コンジュゲート |
| JP2025040440A Pending JP2025090776A (ja) | 2018-12-21 | 2025-03-13 | 生物活性な分子のクラスター |
| JP2025046058A Pending JP2025094140A (ja) | 2018-12-21 | 2025-03-19 | エピトープ結合タンパク質にコンジュゲート化されたサポニン |
| JP2025046059A Pending JP2025102831A (ja) | 2018-12-21 | 2025-03-19 | エピトープ結合タンパク質にコンジュゲート化されたサポニン |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021536414A Active JP7593925B2 (ja) | 2018-12-21 | 2019-12-09 | 改善された抗体－オリゴヌクレオチドコンジュゲート |
| JP2021536407A Active JP7652695B2 (ja) | 2018-12-21 | 2019-12-09 | 生物活性な分子のクラスター |
| JP2021536410A Active JP7502301B2 (ja) | 2018-12-21 | 2019-12-09 | 改善された細胞標的化結合分子 |
Family Applications After (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021536411A Active JP7541008B2 (ja) | 2018-12-21 | 2019-12-09 | サポニンコンジュゲート |
| JP2021536412A Active JP7614094B2 (ja) | 2018-12-21 | 2019-12-09 | 薬物コンジュゲート |
| JP2024199932A Pending JP2025015702A (ja) | 2018-12-21 | 2024-11-15 | 改善された抗体－オリゴヌクレオチドコンジュゲート |
| JP2024230339A Pending JP2025041928A (ja) | 2018-12-21 | 2024-12-26 | 薬物コンジュゲート |
| JP2025040440A Pending JP2025090776A (ja) | 2018-12-21 | 2025-03-13 | 生物活性な分子のクラスター |
| JP2025046058A Pending JP2025094140A (ja) | 2018-12-21 | 2025-03-19 | エピトープ結合タンパク質にコンジュゲート化されたサポニン |
| JP2025046059A Pending JP2025102831A (ja) | 2018-12-21 | 2025-03-19 | エピトープ結合タンパク質にコンジュゲート化されたサポニン |
Country Status (16)
| Country | Link |
|---|---|
| US (10) | US20230173085A1 (cg-RX-API-DMAC7.html) |
| EP (16) | EP3915587B1 (cg-RX-API-DMAC7.html) |
| JP (11) | JP7593925B2 (cg-RX-API-DMAC7.html) |
| KR (9) | KR20210107073A (cg-RX-API-DMAC7.html) |
| CN (8) | CN113747923A (cg-RX-API-DMAC7.html) |
| AU (9) | AU2019408811A1 (cg-RX-API-DMAC7.html) |
| BR (2) | BR112021012225A8 (cg-RX-API-DMAC7.html) |
| CA (6) | CA3124129A1 (cg-RX-API-DMAC7.html) |
| DK (4) | DK3897735T3 (cg-RX-API-DMAC7.html) |
| ES (5) | ES3038616T3 (cg-RX-API-DMAC7.html) |
| IL (8) | IL284279A (cg-RX-API-DMAC7.html) |
| MX (2) | MX2021007449A (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ778378A (cg-RX-API-DMAC7.html) |
| PT (2) | PT4015003T (cg-RX-API-DMAC7.html) |
| SG (8) | SG11202106603UA (cg-RX-API-DMAC7.html) |
| WO (8) | WO2020126064A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017220751A1 (en) | 2016-06-22 | 2017-12-28 | Proqr Therapeutics Ii B.V. | Single-stranded rna-editing oligonucleotides |
| CN110352244B (zh) | 2016-09-01 | 2023-03-21 | ProQR治疗上市公司Ⅱ | 化学修饰的编辑rna的单链寡核苷酸 |
| WO2018204477A1 (en) | 2017-05-02 | 2018-11-08 | Cornell University | Methods and reagents for tumor targeting with greater efficacy and less toxicity |
| GB201808146D0 (en) | 2018-05-18 | 2018-07-11 | Proqr Therapeutics Ii Bv | Stereospecific Linkages in RNA Editing Oligonucleotides |
| SG11202106603UA (en) | 2018-12-21 | 2021-07-29 | Sapreme Tech Bv | Biologically active cluster of molecules |
| ES3056941T3 (en) * | 2019-07-25 | 2026-02-25 | Sapreme Tech Bv | Saponin derivatives with improved therapeutic window |
| ES2931037T3 (es) * | 2019-12-18 | 2022-12-23 | Univ Berlin Freie | Herramienta eficiente de administración de genes con un amplio margen terapéutico |
| CN113527496B (zh) * | 2020-04-16 | 2022-03-04 | 上海洛启生物医药技术有限公司 | 抗Trop2纳米抗体及其应用 |
| KR20230044195A (ko) * | 2020-06-24 | 2023-04-03 | 사프렘 테크놀로지스 비.브이. | 항체-약물 접합체와 항체-사포닌 접합체의 조합물 |
| AU2020454675B2 (en) * | 2020-06-24 | 2025-06-26 | Sapreme Technologies B.V. | Combination comprising an ADC or an AOC comprising a VHH, and a saponin or a ligand-saponin conjugate |
| WO2021260054A2 (en) * | 2020-06-24 | 2021-12-30 | Sapreme Technologies B.V. | Saponin derivatives with improved therapeutic window |
| AU2021295358B2 (en) * | 2020-06-24 | 2026-01-22 | Sapreme Technologies B.V. | Conjugate of galnac and saponin, therapeutic composition comprising said conjugate and a galnac-oligonucleotide conjugate |
| KR20230043118A (ko) * | 2020-06-24 | 2023-03-30 | 사프렘 테크놀로지스 비.브이. | 사포닌 및 단일-도메인 항체의 접합체, 상기 접합체를 포함하는 약학적 조성물, 이의 치료 용도 |
| AU2021296983A1 (en) * | 2020-06-24 | 2023-02-23 | Sapreme Technologies B.V. | Therapeutic combination of galnac-oligonucleotide conjugate and saponin, and uses thereof |
| EP4171645A2 (en) * | 2020-06-24 | 2023-05-03 | Sapreme Technologies B.V. | Hydrazone-based saponin derivatives |
| WO2021261992A1 (en) * | 2020-06-24 | 2021-12-30 | Sapreme Technologies B.V. | Conjugate of galnac and saponin, therapeutic composition comprising said conjugate and a galnac-oligonucleotide conjugate |
| WO2022055351A1 (en) * | 2020-09-10 | 2022-03-17 | Sapreme Technologies B.V. | Conjugate of saponin, oligonucleotide and galnac |
| US20240066045A1 (en) * | 2020-09-10 | 2024-02-29 | Sapreme Technologies B.V. | Semicarbazone-based saponin conjugate |
| JP2023542500A (ja) * | 2020-09-10 | 2023-10-10 | サプリーム テクノロジーズ，ベー．フェー． | サポニン、オリゴヌクレオチド、及びｇａｌｎａｃのコンジュゲート |
| WO2022055352A1 (en) * | 2020-09-10 | 2022-03-17 | Sapreme Technologies B.V. | Semicarbazone-based saponin conjugate |
| US10947552B1 (en) | 2020-09-30 | 2021-03-16 | Alpine Roads, Inc. | Recombinant fusion proteins for producing milk proteins in plants |
| US10894812B1 (en) | 2020-09-30 | 2021-01-19 | Alpine Roads, Inc. | Recombinant milk proteins |
| AU2021353004A1 (en) | 2020-09-30 | 2023-04-13 | Nobell Foods, Inc. | Recombinant milk proteins and food compositions comprising the same |
| EP4251206A4 (en) * | 2020-11-24 | 2025-12-24 | Brickbio Inc | PROTEIN DERIVATIVES CONTAINING UNNATURAL AMINO ACIDS AND BRANCHED BINDERS |
| WO2022164316A1 (en) | 2021-01-26 | 2022-08-04 | Sapreme Technologies B.V. | Semicarbazone-based saponin conjugate |
| EP4355369B1 (en) * | 2021-06-18 | 2025-06-18 | Sapreme Technologies B.V. | Conjugate of saponin, oligonucleotide and galnac |
| WO2023038517A1 (en) | 2021-09-09 | 2023-03-16 | Sapreme Technologies B.V. | Semicarbazone-based saponin conjugate |
| JP2025500481A (ja) | 2021-12-22 | 2025-01-09 | サプリーム テクノロジーズ，ベー．フェー． | 筋消耗性障害を治療するための治療用核酸とサポニンとを含む組成物 |
| US20250057971A1 (en) | 2021-12-22 | 2025-02-20 | Sapreme Technologies B.V. | Targeted saponin-nucleic acid conjugates for treatment of muscle wasting disorders |
| US20250295800A1 (en) * | 2021-12-22 | 2025-09-25 | Sapreme Technologies B.V. | Conjugate of a single domain antibody, a saponin and an effector molecule, pharmaceutical composition comprising the same, therapeutic use of said pharmaceutical composition |
| WO2023121444A1 (en) | 2021-12-22 | 2023-06-29 | Sapreme Technologies B.V. | Compositions comprising therapeutic nucleic acid and targeted saponin for the treatment of muscle-wasting disorders |
| KR20240001074A9 (ko) * | 2022-06-24 | 2024-11-13 | 주식회사 피노바이오 | 하나의 항체에 2종의 약물-링커 접합체가 연결된 항체-약물 접합체 |
| US20260027237A1 (en) | 2022-07-15 | 2026-01-29 | Proqr Therapeutics Ii B.V. | Chemically modified oligonucleotides for adar-mediated rna editing |
| JP2025524566A (ja) | 2022-07-15 | 2025-07-30 | プロキューアール セラピューティクス ツー ベスローテン フェンノートシャップ | Ａｄａｒ媒介ｒｎａ編集のためのオリゴヌクレオチドおよびその使用 |
| EP4580682A1 (en) * | 2022-09-01 | 2025-07-09 | Sapreme Technologies B.V. | Compositions of polyplexes and saponins |
| EP4331609A1 (en) * | 2022-09-01 | 2024-03-06 | Sapreme Technologies B.V. | Methods and compositions for enhanced polyplex delivery |
| EP4331610A1 (en) * | 2022-09-01 | 2024-03-06 | Sapreme Technologies B.V. | Polyplex-saponin covalent conjugate |
| CN116259371B (zh) * | 2022-09-09 | 2026-02-17 | 江苏理工学院 | 化合物激素受体活性预测方法和装置 |
| EP4666071A2 (en) * | 2023-02-13 | 2025-12-24 | Nautilus Subsidiary, Inc. | Affinity reagents having artificial polymer scaffolds |
| CN118852442A (zh) | 2023-04-26 | 2024-10-29 | 上海麦科思生物医药有限公司 | 抗ptk7抗体及其用途 |
| WO2024238981A1 (en) * | 2023-05-18 | 2024-11-21 | Vycellix, Inc. | Plasma membrane embedded system for spaciotemporal controlled payload delivery of biologics |
| EP4731257A1 (en) | 2023-06-21 | 2026-04-29 | Sapreme Technologies B.V. | Conjugates of saponin and antisense oligonucleotides for use in the treatment of neurodegenerative diseases |
| AU2024312000A1 (en) | 2023-06-21 | 2026-02-05 | Sapreme Technologies B.V. | Pharmaceutical compositions for treatment of central nervous system disorders |
| WO2025222234A1 (en) * | 2024-04-24 | 2025-10-30 | Starpharma Pty Ltd | Targeted dendrimer conjugates |
| EP4684805A1 (en) * | 2024-07-24 | 2026-01-28 | Universitätsmedizin der Johannes Gutenberg-Universität Mainz | Selective antibody-drug conjugates for targeted cancer therapy |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0058021A3 (en) | 1981-02-06 | 1982-10-27 | Beecham Group Plc | Pharmaceutical compositions |
| US5591829A (en) * | 1987-05-29 | 1997-01-07 | Matsushita; Shuzo | Antibodies modified with toxic substance |
| US5583112A (en) | 1987-05-29 | 1996-12-10 | Cambridge Biotech Corporation | Saponin-antigen conjugates and the use thereof |
| US5273965A (en) | 1992-07-02 | 1993-12-28 | Cambridge Biotech Corporation | Methods for enhancing drug delivery with modified saponins |
| US5856571A (en) | 1995-06-07 | 1999-01-05 | Cellpro, Incorporated | Semicarbazide-containing linker compounds for formation of stably-linked conjugates and methods related thereto |
| DE69828507T2 (de) * | 1997-05-20 | 2006-01-05 | Galenica Pharmaceuticals, Inc. | Triterpene-saponin analoga mit adjuvans und immunostimulierender wirkung |
| WO2000009075A2 (en) * | 1998-08-14 | 2000-02-24 | Galenica Pharmaceuticals, Inc. | Chemically modified saponins and the use thereof as adjuvants |
| US7256257B2 (en) * | 2001-04-30 | 2007-08-14 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
| JP2005525344A (ja) * | 2002-02-04 | 2005-08-25 | コリクサ コーポレイション | アミノアルキルグルコサミニドホスフェートおよびサポニンを含む免疫刺激性組成物 |
| US7112573B2 (en) * | 2002-04-19 | 2006-09-26 | Iowa Research, The University Foundation | Isoflavone and triterpene glycosides from soybeans |
| WO2004092329A2 (en) | 2003-04-08 | 2004-10-28 | Galenica Pharmaceuticals, Inc. | Semi-synthetic saponin analogs with carrier and immune stimulatory activities for dna and rna vaccines |
| EP1623715B1 (en) * | 2004-07-13 | 2012-09-19 | Charité - Universitätsmedizin Berlin | A composition comprising a pharmacologically active agent coupled to a target cell specific component, and a saponin |
| JP2008510829A (ja) | 2004-08-25 | 2008-04-10 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | デンドリマーに基づく組成物およびそれらの使用法 |
| CA2631184A1 (en) | 2005-11-28 | 2007-05-31 | Genmab A/S | Recombinant monovalent antibodies and methods for production thereof |
| DK2094278T3 (en) | 2006-11-20 | 2017-07-24 | Duecom | USE OF LIPID-CONTAINING PARTICLES INCLUDING QUILLAJA SAPONINS FOR CANCER TREATMENT |
| US20080311040A1 (en) * | 2007-03-06 | 2008-12-18 | Flagship Ventures | METHODS AND COMPOSITIONS FOR IMPROVED THERAPEUTIC EFFECTS WITH siRNA |
| EP2282752A4 (en) * | 2008-03-26 | 2011-06-15 | Ca Nat Research Council | SAPONIN EXTRACT FROM SAPONARIA SPP AND ITS USES |
| WO2009126913A1 (en) * | 2008-04-11 | 2009-10-15 | Cedars-Sinai Medical Center | Poly(beta malic acid) with pendant leu-leu-leu tripeptide for effective cytoplasmic drug delivery |
| WO2011054811A1 (en) * | 2009-11-03 | 2011-05-12 | Santaris Pharma A/S | Rna antagonists targeting hsp27 combination therapy |
| MX2012013001A (es) * | 2010-05-13 | 2013-02-26 | Univ Indiana Res & Tech Corp | Peptidos de la superfamilia de glucagon que presentan actividad del receptor nuclear de hormonas. |
| US9125835B2 (en) * | 2010-11-12 | 2015-09-08 | Rutgers, The State University Of New Jersey | Synergistic combinations to reduce particle dose for targeted treatment of cancer and its metastases |
| CN102652836A (zh) | 2011-03-03 | 2012-09-05 | 华中科技大学同济医学院附属协和医院 | 靶向释药的抗癌蛋白质或多肽聚合物前药及其制备方法 |
| SG11201403085PA (en) * | 2011-12-14 | 2014-10-30 | Seattle Genetics Inc | Fgfr antibody drug conjugates (adcs) and the use thereof |
| JP6408478B2 (ja) * | 2012-11-26 | 2018-10-17 | プレジデント アンド フェローズ オブ ハーバード カレッジ | トリオキサカルシン、トリオキサカルシン−抗体複合体、およびその用途 |
| AR095962A1 (es) * | 2013-04-01 | 2015-11-25 | Moreinx Ab | Nanopartículas, compuestas de esterol y saponina de quillaja saponaria molina, proceso para preparación y uso de las mismas como portadores para moléculas anfipáticas o hidrófobas en el campo de la medicina incluyendo tratamiento de cáncer y compuestos relacionados con alimentos |
| GB201400994D0 (en) | 2014-01-21 | 2014-03-05 | Ucl Business Plc | Drug delivery system |
| JP6685924B2 (ja) * | 2014-04-11 | 2020-04-22 | メディミューン，エルエルシー | システイン操作抗体を含むコンジュゲート化合物 |
| KR102424785B1 (ko) | 2014-05-30 | 2022-07-25 | 메모리얼 슬로안 케터링 캔서 센터 | 최소 사포닌 유사체, 이의 합성법 및 용도 |
| TW201617368A (zh) * | 2014-09-05 | 2016-05-16 | 史坦森特瑞斯公司 | 新穎抗ｍｆｉ２抗體及使用方法 |
| CN106892957B (zh) * | 2015-12-17 | 2018-11-16 | 广州中医药大学 | 一种齐墩果烷型三萜皂苷类化合物及其制备方法和应用 |
| MX2018015285A (es) * | 2016-06-08 | 2019-09-18 | Abbvie Inc | Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco. |
| WO2018057031A1 (en) | 2016-09-26 | 2018-03-29 | Natural Response, S.A. | Production of biomass in ultra high density plantations |
| US11708388B2 (en) | 2017-07-11 | 2023-07-25 | Freie Universität Berlin | Uses of a saponin and method for its isolation |
| SG11202106603UA (en) | 2018-12-21 | 2021-07-29 | Sapreme Tech Bv | Biologically active cluster of molecules |
| ES3056941T3 (en) | 2019-07-25 | 2026-02-25 | Sapreme Tech Bv | Saponin derivatives with improved therapeutic window |
| WO2022055352A1 (en) * | 2020-09-10 | 2022-03-17 | Sapreme Technologies B.V. | Semicarbazone-based saponin conjugate |
-
2019
- 2019-12-09 SG SG11202106603UA patent/SG11202106603UA/en unknown
- 2019-12-09 KR KR1020217023075A patent/KR20210107073A/ko not_active Ceased
- 2019-12-09 EP EP21186481.4A patent/EP3915587B1/en active Active
- 2019-12-09 EP EP19820708.6A patent/EP3897741A1/en active Pending
- 2019-12-09 CN CN201980092673.5A patent/CN113747923A/zh active Pending
- 2019-12-09 DK DK19817689.3T patent/DK3897735T3/da active
- 2019-12-09 WO PCT/EP2019/000334 patent/WO2020126064A1/en not_active Ceased
- 2019-12-09 DK DK19835231.2T patent/DK3773737T3/da active
- 2019-12-09 AU AU2019408811A patent/AU2019408811A1/en active Pending
- 2019-12-09 KR KR1020217023032A patent/KR102894465B1/ko active Active
- 2019-12-09 SG SG11202106672SA patent/SG11202106672SA/en unknown
- 2019-12-09 CA CA3124129A patent/CA3124129A1/en active Pending
- 2019-12-09 KR KR1020217023063A patent/KR20210119978A/ko not_active Ceased
- 2019-12-09 ES ES23170913T patent/ES3038616T3/es active Active
- 2019-12-09 CN CN201980092709.XA patent/CN113507941A/zh active Pending
- 2019-12-09 KR KR1020217022975A patent/KR20210110323A/ko active Pending
- 2019-12-09 EP EP19835231.2A patent/EP3773737B1/en active Active
- 2019-12-09 KR KR1020217023071A patent/KR20210117274A/ko not_active Ceased
- 2019-12-09 ES ES19817677T patent/ES2985240T3/es active Active
- 2019-12-09 CN CN201980092610.XA patent/CN113498350A/zh active Pending
- 2019-12-09 US US17/312,311 patent/US20230173085A1/en not_active Abandoned
- 2019-12-09 EP EP25172979.4A patent/EP4588523A3/en active Pending
- 2019-12-09 CA CA3124065A patent/CA3124065A1/en active Pending
- 2019-12-09 AU AU2019411276A patent/AU2019411276A1/en active Pending
- 2019-12-09 US US17/312,104 patent/US20220023433A1/en active Pending
- 2019-12-09 JP JP2021536414A patent/JP7593925B2/ja active Active
- 2019-12-09 PT PT212121842T patent/PT4015003T/pt unknown
- 2019-12-09 EP EP19817677.8A patent/EP3897739B1/en active Active
- 2019-12-09 BR BR112021012225A patent/BR112021012225A8/pt not_active IP Right Cessation
- 2019-12-09 SG SG11202106575YA patent/SG11202106575YA/en unknown
- 2019-12-09 JP JP2021536407A patent/JP7652695B2/ja active Active
- 2019-12-09 EP EP19817676.0A patent/EP3897742A2/en active Pending
- 2019-12-09 SG SG11202106606RA patent/SG11202106606RA/en unknown
- 2019-12-09 ES ES19835231T patent/ES2899612T3/es active Active
- 2019-12-09 AU AU2019400630A patent/AU2019400630B2/en active Active
- 2019-12-09 US US17/312,019 patent/US12453782B2/en active Active
- 2019-12-09 CN CN202510084422.XA patent/CN119868574A/zh active Pending
- 2019-12-09 CN CN201980092858.6A patent/CN113474009A/zh active Pending
- 2019-12-09 KR KR1020217023074A patent/KR20210117275A/ko active Pending
- 2019-12-09 JP JP2021536410A patent/JP7502301B2/ja active Active
- 2019-12-09 JP JP2021536413A patent/JP7654546B2/ja active Active
- 2019-12-09 JP JP2021536411A patent/JP7541008B2/ja active Active
- 2019-12-09 EP EP19817672.9A patent/EP3897743A1/en active Pending
- 2019-12-09 US US17/312,193 patent/US20220054643A1/en active Pending
- 2019-12-09 CA CA3124406A patent/CA3124406A1/en active Pending
- 2019-12-09 NZ NZ778378A patent/NZ778378A/en unknown
- 2019-12-09 AU AU2019407234A patent/AU2019407234B2/en active Active
- 2019-12-09 AU AU2019411278A patent/AU2019411278B2/en active Active
- 2019-12-09 US US17/312,403 patent/US20220111066A1/en not_active Abandoned
- 2019-12-09 EP EP19817689.3A patent/EP3897735B1/en active Active
- 2019-12-09 WO PCT/EP2019/084290 patent/WO2020126626A1/en not_active Ceased
- 2019-12-09 MX MX2021007449A patent/MX2021007449A/es unknown
- 2019-12-09 BR BR112021012222A patent/BR112021012222A8/pt not_active Application Discontinuation
- 2019-12-09 CA CA3124064A patent/CA3124064A1/en active Pending
- 2019-12-09 US US17/312,476 patent/US20220072149A1/en active Pending
- 2019-12-09 EP EP23166479.8A patent/EP4223316A3/en active Pending
- 2019-12-09 ES ES19817689T patent/ES3059876T3/es active Active
- 2019-12-09 AU AU2019411289A patent/AU2019411289B2/en active Active
- 2019-12-09 CN CN202510019306.XA patent/CN119950740A/zh active Pending
- 2019-12-09 CN CN201980092771.9A patent/CN113453722A/zh active Pending
- 2019-12-09 JP JP2021536412A patent/JP7614094B2/ja active Active
- 2019-12-09 EP EP19817682.8A patent/EP3856254A2/en active Pending
- 2019-12-09 US US17/415,759 patent/US20220218837A1/en active Pending
- 2019-12-09 WO PCT/EP2019/084242 patent/WO2020126620A2/en not_active Ceased
- 2019-12-09 DK DK21212184.2T patent/DK4015003T5/da active
- 2019-12-09 EP EP19817673.7A patent/EP3897738B1/en active Active
- 2019-12-09 EP EP21212184.2A patent/EP4015003B1/en active Active
- 2019-12-09 EP EP25203109.1A patent/EP4647436A3/en active Pending
- 2019-12-09 PT PT198176893T patent/PT3897735T/pt unknown
- 2019-12-09 CN CN201980092811.XA patent/CN113474010A/zh active Pending
- 2019-12-09 MX MX2021007296A patent/MX2021007296A/es unknown
- 2019-12-09 WO PCT/EP2019/084211 patent/WO2020126610A1/en not_active Ceased
- 2019-12-09 CA CA3123978A patent/CA3123978A1/en active Pending
- 2019-12-09 EP EP20209450.4A patent/EP3808379A1/en active Pending
- 2019-12-09 WO PCT/EP2019/084292 patent/WO2020126627A1/en not_active Ceased
- 2019-12-09 KR KR1020257035339A patent/KR20250160210A/ko active Pending
- 2019-12-09 WO PCT/EP2019/084180 patent/WO2020126600A1/en not_active Ceased
- 2019-12-09 EP EP23170913.0A patent/EP4241847B1/en active Active
- 2019-12-09 WO PCT/EP2019/084210 patent/WO2020126609A2/en not_active Ceased
- 2019-12-09 SG SG11202106574UA patent/SG11202106574UA/en unknown
- 2019-12-09 DK DK19817673.7T patent/DK3897738T5/da active
- 2019-12-09 WO PCT/EP2019/084190 patent/WO2020126604A1/en not_active Ceased
- 2019-12-09 ES ES21212184T patent/ES2952017T3/es active Active
- 2019-12-09 CA CA3124151A patent/CA3124151A1/en active Pending
- 2019-12-09 SG SG11202106664PA patent/SG11202106664PA/en unknown
- 2019-12-09 SG SG11202106612QA patent/SG11202106612QA/en unknown
- 2019-12-09 KR KR1020217023069A patent/KR20210119979A/ko not_active Ceased
- 2019-12-09 KR KR1020217023076A patent/KR20210117276A/ko active Pending
- 2019-12-09 US US17/413,965 patent/US20250195682A1/en active Pending
- 2019-12-09 EP EP24169240.9A patent/EP4374927A3/en active Pending
- 2019-12-09 SG SG11202106572QA patent/SG11202106572QA/en unknown
-
2021
- 2021-06-21 IL IL284279A patent/IL284279A/en unknown
- 2021-06-21 IL IL284278A patent/IL284278A/en unknown
- 2021-06-21 IL IL284265A patent/IL284265A/en unknown
- 2021-06-21 IL IL284274A patent/IL284274A/en unknown
- 2021-06-21 IL IL284272A patent/IL284272A/en unknown
- 2021-06-21 IL IL284273A patent/IL284273A/en unknown
- 2021-06-21 IL IL284280A patent/IL284280A/en unknown
- 2021-06-21 IL IL284276A patent/IL284276A/en unknown
-
2024
- 2024-11-15 JP JP2024199932A patent/JP2025015702A/ja active Pending
- 2024-12-16 US US18/981,715 patent/US20250302983A1/en active Pending
- 2024-12-26 JP JP2024230339A patent/JP2025041928A/ja active Pending
-
2025
- 2025-02-04 US US19/044,661 patent/US20260000783A1/en active Pending
- 2025-03-13 JP JP2025040440A patent/JP2025090776A/ja active Pending
- 2025-03-19 JP JP2025046058A patent/JP2025094140A/ja active Pending
- 2025-03-19 JP JP2025046059A patent/JP2025102831A/ja active Pending
- 2025-03-28 AU AU2025202242A patent/AU2025202242A1/en active Pending
- 2025-04-29 AU AU2025203017A patent/AU2025203017A1/en active Pending
- 2025-04-30 AU AU2025203092A patent/AU2025203092A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022516045A5 (cg-RX-API-DMAC7.html) | ||
| JP7652695B2 (ja) | 生物活性な分子のクラスター | |
| JP2025090795A (ja) | Ｖｈｈを含むａｄｃ又はａｏｃと、サポニン又はリガンド－サポニンコンジュゲートとを含む組み合わせ | |
| WO2021259507A1 (en) | Conjugate of a single domain antibody, a saponin and an effector molecule, pharmaceutical composition comprising the same, therapeutic use of said pharmaceutical composition | |
| US20240229033A1 (en) | Compositions for Inhibiting Growth of Targeted Cells | |
| JP2025090796A (ja) | 単一ドメイン抗体、サポニン及びエフェクター分子のコンジュゲート、それを含む医薬組成物、前記医薬組成物の治療的使用 | |
| CN116249553A (zh) | 抗体-药物缀合物和抗体-皂苷缀合物的组合 | |
| US20250295800A1 (en) | Conjugate of a single domain antibody, a saponin and an effector molecule, pharmaceutical composition comprising the same, therapeutic use of said pharmaceutical composition | |
| JP2023532003A5 (cg-RX-API-DMAC7.html) | ||
| RU2021121380A (ru) | Улучшенная клеточно-таргетная связующая молекула | |
| NZ778372B2 (en) | Biologically active cluster of molecules | |
| Zaro et al. | Summary and Future Directions of Antibody-Drug Conjugates | |
| RU2021121414A (ru) | Биологически активный кластер молекул | |
| HK40130827A (en) | Combination comprising an adc or an aoc comprising a vhh, and a saponin or a ligand-saponin conjugate | |
| CN121219012A (zh) | 用于治疗癌症的双有效载荷抗体药物缀合物 |